MENU
NNNN
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION

NNNN stock forecast, quote, news & analysis

Anbio Biotechnology is a medical device company focused on in vitro diagnostics... Show more

NNNN
Daily Signal:
Gain/Loss:
A.I.Advisor
published price charts
Interact to see
Advertisement
A.I.Advisor
a Summary for NNNN with price predictions
Oct 01, 2026

NNNN sees its Stochastic Oscillator climbs out of oversold territory

On September 23, 2026, the Stochastic Oscillator for NNNN moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 20 instances where the indicator left the oversold zone. In 19 of the 20 cases the stock moved higher in the following days. This puts the odds of a move higher at over 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where NNNN's RSI Indicator exited the oversold zone, 7 of 8 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 88%.

The Momentum Indicator moved above the 0 level on September 29, 2026. You may want to consider a long position or call options on NNNN as a result. In 28 of 28 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 90%.

The Moving Average Convergence Divergence (MACD) for NNNN just turned positive on September 21, 2026. Looking at past instances where NNNN's MACD turned positive, the stock continued to rise in 11 of 11 cases over the following month. The odds of a continued upward trend are 90%.

Following a +3.45% 3-day Advance, the price is estimated to grow further. Considering data from situations where NNNN advanced for three days, in 90 of 92 cases, the price rose further within the following month. The odds of a continued upward trend are 90%.

NNNN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

Following a 3-day decline, the stock is projected to fall further. Considering past instances where NNNN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

The Aroon Indicator for NNNN entered a downward trend on September 29, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 61 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (8.865) is normal, around the industry mean (5.011). P/E Ratio (40.884) is within average values for comparable stocks, (163.451). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (4.456). Dividend Yield (0.000) settles around the average of (0.005) among similar stocks. P/S Ratio (28.169) is also within normal values, averaging (56.074).

The Tickeron Price Growth Rating for this company is 92 (best 1 - 100 worst), indicating slightly worse than average price growth. NNNN’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NNNN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 96, placing this stock worse than average.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Intuitive Surgical (NASDAQ:ISRG), Align Technology (NASDAQ:ALGN).

Industry description

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

Market Cap

The average market capitalization across the Pharmaceuticals: Other Industry is 8.89B. The market cap for tickers in the group ranges from 126 to 146.54B. ISRG holds the highest valuation in this group at 146.54B. The lowest valued company is HGYMF at 126.

High and low price notable news

The average weekly price growth across all stocks in the Pharmaceuticals: Other Industry was -2%. For the same Industry, the average monthly price growth was -5%, and the average quarterly price growth was 14%. CUPR experienced the highest price growth at 34%, while NXGL experienced the biggest fall at -32%.

Volume

The average weekly volume growth across all stocks in the Pharmaceuticals: Other Industry was 2%. For the same stocks of the Industry, the average monthly volume growth was 30% and the average quarterly volume growth was 19%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 57
P/E Growth Rating: 58
Price Growth Rating: 54
SMR Rating: 81
Profit Risk Rating: 96
Seasonality Score: 15 (-100 ... +100)
View a ticker or compare two or three
NNNN
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

Industry PharmaceuticalsOther

Industry
N/A
Address
Friedrich-Ebert-Anlage 35-37
Phone
+49 69870039170
Employees
27
Web
https://www.anbio.com
NNNN sees its Stochastic Oscillator climbs out of oversold territory